drugset
drugset / Trial / NCT05229315

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

NCT05229315 ↗

Phase 2 Unknown 45 enrolled XIANG YANQUN
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of PD-1 immune checkpoint inhibitor combined with intensity modulated radiation therapy in the treatment of intermediate-risk nasopharyngeal carcinoma (T2-3N0 or T1-2N1 stage and EBV-DNA≤4000 copy/ml).

Timeline

Start
2022-03-12
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody — —

Indications

nasopharyngeal carcinoma